Market revenue in 2020 | USD 17.5 million |
Market revenue in 2028 | USD 36.0 million |
Growth rate | 9.4% (CAGR from 2020 to 2028) |
Largest segment | Cancer |
Fastest growing segment | Hematology Diseases |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 14.29% in 2020. Horizon Databook has segmented the Brazil rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
With growing awareness, it has become a necessity to formally incorporate medical genetics into the healthcare system in Brazil. Introduction of national policies such as “Policy for the Integral Attention to Subjects with Rare Diseases” by Ministry of Health is one of the initiative towards this direction.
In addition, several other initiatives are being undertaken in the country to advance service offerings, promoting awareness and developing research in this area. Furthermore, a substantial number of universities and hospitals are engaged in publishing reports pertaining to the clinical research.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account